Bristol Myers Squibb is expanding its Nvidia partnership to build what it describes as one of the most powerful AI supercomputer systems in life sciences. The effort, often framed as an “AI factory,” is intended to accelerate BMS drug discovery workflows. BMS Chief Research Officer Robert Plenge said the company already cut the length of the process by 20% to 30% using AI tools, highlighting measurable cycle-time gains. Nvidia similarly has multiple life-sciences computing deals, placing BMS alongside peers moving compute-intensive AI into discovery. For biotech R&D teams, this is a signal that AI execution is shifting from pilot projects to dedicated infrastructure partnerships—potentially reshaping how quickly compounds move from design into experimentally testable hypotheses.